Literature DB >> 12424005

The pharmaceutical industry as an informant.

Joe Collier1, Ike Iheanacho.   

Abstract

The pharmaceutical industry spends more time and resources on generation, collation, and dissemination of medical information than it does on production of medicines. This information is essential as a resource for development of medicines, but is also needed to satisfy licensing requirements, protect patents, promote sales, and advise patients, prescribers, and dispensers. Such information is of great commercial value, and most of it is confidential, protected by regulations about intellectual property rights. Through their generation and dissemination of information, transnational companies can greatly influence clinical practice. Sometimes, their commercially determined goals represent genuine advances in health-care provision, but most often they are implicated in excessive and costly production of information that is largely kept secret, often duplicated, and can risk undermining the best interests of patients and society.

Entities:  

Keywords:  Biomedical and Behavioral Research; Health Care and Public Health

Mesh:

Year:  2002        PMID: 12424005     DOI: 10.1016/S0140-6736(02)11394-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  Fewer new drugs from the pharmaceutical industry.

Authors:  David Taylor
Journal:  BMJ       Date:  2003-02-22

2.  [Psychiatrists and the pharmaceutical industry].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

3.  Getting it right: industry sponsorship and medical research.

Authors:  Patricia Baird
Journal:  CMAJ       Date:  2003-05-13       Impact factor: 8.262

4.  Information from drug companies and opinion leaders.

Authors:  Alessandro Liberati; Nicola Magrini
Journal:  BMJ       Date:  2003-05-31

5.  Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  Jeffrey Barkun; Nicolas V Christou
Journal:  Can J Surg       Date:  2003-12       Impact factor: 2.089

6.  Patent nonsense: evidence tells of an industry out of social control.

Authors:  Henry Mintzberg
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

7.  Public welfare agenda or corporate research agenda?

Authors:  Ajai Singh; Shakuntala Singh
Journal:  Mens Sana Monogr       Date:  2005-03

8.  Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trials.

Authors:  Nicola Magrini; Giulio Formoso; Oreste Capelli; Emilio Maestri; Francesco Nonino; Barbara Paltrinieri; Cinzia Del Giovane; Claudio Voci; Lucia Magnano; Lisa Daya; Anna Maria Marata
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  Randomised controlled trials for evaluating the prescribing impact of information meetings led by pharmacists and of new information formats, in General Practice in Italy.

Authors:  Nicola Magrini; Giulio Formoso; Anna Maria Marata; Oreste Capelli; Emilio Maestri; Claudio Voci; Francesco Nonino; Massimo Brunetti; Barbara Paltrinieri; Susanna Maltoni; Lucia Magnano; Maria Isabella Bonacini; Lisa Daya; Nilla Viani
Journal:  BMC Health Serv Res       Date:  2007-09-28       Impact factor: 2.655

Review 10.  Pipeline of Known Chemical Classes of Antibiotics.

Authors:  Cristina d'Urso de Souza Mendes; Adelaide Maria de Souza Antunes
Journal:  Antibiotics (Basel)       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.